Equillium, Inc.
EQ
NASDAQ·Healthcare·Biotechnology·Mkt cap $139.7M
$2.21
▼ -0.45%
P/E
-8.46
Mkt Cap
$139.7M
52-Wk Range
$0.76–$3.54
52-Week Range
$0.76 - $3.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CD6-targeting monoclonal antibody technology with novel immune checkpoint mechanism
- Diversified clinical pipeline addressing multiple high-value therapeutic areas with unmet medical needs
- Advanced clinical development stage with Phase III trials providing near-term catalysts for value creation
- Experienced biotechnology team in La Jolla biotech hub with focus on immunotherapy innovation
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Stable outlook
Successful Phase III trial results for itolizumab in acute graft-versus-host disease with potential regulatory approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-20.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EQ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.04 vs -$0.05 consensus (+25.9% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+25.9%
Revenue trend · last 8Q
—
—
-100%
-100%
-100%
-100%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$12.2M
$4.4M
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Jul 13, 2026
vs Industry
How EQ stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related